Dr. John A. Catanzaro, CEO and Co-founder of Neo7 Bioscience, discusses groundbreaking personalized peptide therapies for advanced cancer patients. He highlights how mRNA and designer peptides can serve as targeted treatments, emphasizing the need for individualized approaches to combat treatment resistance. The conversation covers the optimization of therapy with antihistamines and steroid pre-treatments, innovative investigational products, and the hopeful future of personalized medicine as a game changer in cancer care.
